Benitec Biopharma (NASDAQ:BNTC) Lowered to “Sell” Rating by Wall Street Zen

Posted by Francis Steltz on Sep 20th, 2026

Wall Street Zen cut shares of Benitec Biopharma (NASDAQ:BNTC – Free Report) from a hold rating to a sell rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

Several other analysts also recently weighed in on BNTC. Guggenheim downgraded Benitec Biopharma from a “buy” rating to a “neutral” rating in a research note on Wednesday, June 10th. Wedbush lifted their price objective on Benitec Biopharma from $16.00 to $17.00 and gave the company an “outperform” rating in a research note on Tuesday, September 15th. Citigroup reissued a “market outperform” rating on shares of Benitec Biopharma in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Benitec Biopharma in a research note on Friday, July 17th. Finally, Royal Bank Of Canada upgraded Benitec Biopharma to an “outperform” rating in a report on Tuesday. Seven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $24.00.

View Our Latest Stock Report on BNTC

Benitec Biopharma Price Performance

NASDAQ:BNTC opened at $11.02 on Friday. The firm’s 50-day moving average price is $12.43 and its 200-day moving average price is $12.03. The company has a market capitalization of $384.38 million, a PE ratio of -11.24 and a beta of 0.27. Benitec Biopharma has a 1-year low of $9.85 and a 1-year high of $16.76.

Benitec Biopharma (NASDAQ:BNTC – Get Free Report) last posted its quarterly earnings data on Monday, September 14th. The biotechnology company reported ($0.26) EPS for the quarter, hitting the consensus estimate of ($0.26). Equities analysts anticipate that Benitec Biopharma will post -1.29 EPS for the current fiscal year.

Institutional Trading of Benitec Biopharma

Institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC boosted its holdings in Benitec Biopharma by 18.7% in the second quarter. GAMMA Investing LLC now owns 7,961 shares of the biotechnology company’s stock worth $107,000 after purchasing an additional 1,256 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Benitec Biopharma by 43.3% in the first quarter. Bank of America Corp DE now owns 17,376 shares of the biotechnology company’s stock worth $185,000 after acquiring an additional 5,251 shares during the period. ADAR1 Capital Management LLC purchased a new stake in Benitec Biopharma during the first quarter valued at $186,000. Bank of New York Mellon Corp boosted its position in Benitec Biopharma by 37.6% in the first quarter. Bank of New York Mellon Corp now owns 43,489 shares of the biotechnology company’s stock worth $463,000 after purchasing an additional 11,877 shares during the last quarter. Finally, Empery Asset Management LP bought a new stake in shares of Benitec Biopharma during the 4th quarter valued at about $747,000. Hedge funds and other institutional investors own 52.19% of the company’s stock.

Benitec Biopharma Company Profile

(Get Free Report)

Benitec Biopharma Inc (NASDAQ:BNTC) is a clinical-stage biotechnology company developing genetic medicines based on DNA-directed RNA interference (ddRNAi). The company’s technology is designed to enable long-lasting suppression of disease-causing genes by delivering genetic instructions that produce RNA interference molecules within targeted cells.

Benitec’s lead product candidate is BB-301, an investigational gene therapy being developed for oculopharyngeal muscular dystrophy type 1 (OPMD), a rare inherited disorder that can cause progressive weakness of the muscles involved in swallowing and eye movement.